Data sharing technology companies Datavant has announced that it will win Aettion, a company focused on real-world evidence of healthcare (RWE).
ADY joins Datavant to provide an end-to-end, real-world evidence platform, enabling medical and life science companies to answer research questions about the clinical impact of development and treatment in the market.
Davavant’s platform allows health care records to move between organizations, including over 70,000 hospitals and clinics.
AETION offers RWE offerings Biopharmaceutical companies, medical device manufacturers, payers, regulatory authorities.
Companies leverage their ability to create end-to-end delivery of data discovery, linking, privacy, curation and advanced analytics, enabling ecosystems and life science partners to create analytics-based insights.
This announcement comes after the launch of Datavant Connect, which features AWS Cleanrooms. This “helps discovery and evaluate cloud-first data, and accelerates time to insight.”
Data can be combined with corresponding data sources via Datavant Connect.
According to both companies, AETION will enhance the Datavant Connect Platform’s data discovery capabilities, enhance privacy ratings, and provide customer datasets and analytics.
Additionally, the AETION Evidence Platform will be available on AWS Marketplaces.
“Real world evidence has reached an inflection point where it has to start to make more sense from data,” according to Arnaub Chatterjee, president and general manager of the life sciences, ecosystems and public sector at Datavant. MobiHealthNews.
“The complementary features of Datavant and ADY are combined to provide new tools to determine data feasibility, queries, evaluation and ultimately fair access to data.
Bigger trends
Datavant extended it This month we collaborated with Pharmaceutical Company Boehringer Ingelheim to support Boehringer’s RWE initiative.
The extended collaboration aims to leverage Datavant’s tokenization and data connectivity technology to improve clinical development and launch strategies with 75 additional clinical trials and multiple new molecular entities.
Boehringer Ingelheim aims to increase the integration of real data into drug development by applying Datavant’s technology to a wide range of testing and launch portfolios.
2023, Socially determined, partnered with Datavant to provide Life Sciences companies with data on social risk drivers to improve health equity and patient outcomes.
In 2021, MindMed turned to datavant to support that link Clinical trial data with external evidence from other clinical trials and real data sources.
A year ago, Datavant was closed Series B funding costs $40 million. Transformation Capital led the round with participation from Johnson & Johnson Innovation, JJDC, Cigna Ventures and former investors Roivant Sciences and Flex Capital.
That same year, Datavant acquired Ciox Health in a deal worth $7 billion. The Total Company focused on improving patient outcomes and reducing costs by removing obstacles to safe health data exchange.
In 2023, AETION collaborated with FDA Oncology Center of Excellence (OCE).
Used OCE An edition evidence platform for finding and analyzing real-world data sources that can be used to study cancer prevention, clinical care, diagnosis and treatment.
This collaboration assessed real-world endpoints, measured healthcare disparities, and assessed causal inference methods. The research was scheduled to continue until 2027.
In 2022, AETION was acquired Replica analysis with new features analysed in synthetic RWE. The announcement comes less than a year after ADY secured a $110 million Series C funding round led by Warburg Pincus.
